Intercept skyrockets 281% on NASH results
This article was originally published in Scrip
Executive Summary
Intercept Pharmaceuticals nearly tripled its stock value on 9 January when the New York-based company reported that a Phase II clinical trial for obeticholic acid (OCA) in the treatment of nonalcoholic steatohepatitis (NASH) was stopped early, because the primary endpoint was met in an interim analysis.
You may also be interested in...
Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets
Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.
Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Finance Watch: VCs Are Sharing The Wealth With More Biopharmas
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Need a specific report? 1000+ reports available
Buy Reports